All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US. We asked: Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?
Anas Younes discusses the concept of using nanoparticles to deliver BCL-2 family inhibitors, such as venetoclax, or an MCL-1 inhibitor, in order to reduce the toxicity seen when a BCL-2 family inhibitor and MCL-1 inhibitor are administered simultaneously. Providing one of these agents via nanoparticles was shown to reduce toxicity in mouse models, potentially providing a new method of administering multiple agents at the same time.
Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
0 votes - 8 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox